Vanderbilt Eye Institute Archive — Page 6 of 9
-
June 25, 2015
Daniels receives research grant from Knights Templar Eye Foundation to study retinoblastoma treatment
Vanderbilt investigator Anthony Daniels has received a grant from the Knights Templar Eye Foundation to develop new, safe and effective treatments for retinoblastoma, the most common ocular cancer in children. -
June 25, 2015
VEI receives grant from Research to Prevent Blindness for research and education
The Vanderbilt Eye Institute recently received a grant for $115,000 from Research to Prevent Blindness, placing the total award amount for unrestricted grants from the organization at $860,000. -
March 23, 2015
Beware the eyes of March: Vanderbilt ophthalmologist offers tips for preventing and treating dry eyes during windy weather
-
February 12, 2015
VUMC’s Penn named president-elect of eye research society
John Penn, Ph.D., Phyllis G and William B. Snyder Endowed Professor of Ophthalmology and Visual Sciences, has been named president-elect of the International Society for Eye Research (ISER). -
December 16, 2014
Retinal neuron survival in glaucoma
Understanding how the protein TRPV1 helps neurons survive after glaucoma-related stressors could lead to new therapeutic strategies for glaucoma and other neurodegenerative conditions. -
October 16, 2014
Project PAVE’s impact on children’s vision easy to see
It’s been 20 years since Project PAVE, a Tennessee program providing low-vision evaluations for children, was launched. -
October 9, 2014
Novel therapy eases stress of retinoblastoma treatment
Conventional therapy for patients diagnosed with retinoblastoma, the most common ocular cancer in children, includes systemic chemotherapy, external beam radiation and/or surgical removal of the eye. Doctors at Vanderbilt University Medical Center are on track to radically change the way the disease is treated using an emerging therapeutic approach called intra-arterial chemotherapy, or IA chemo.